- Home
- TOPS vs CGTX Comparison
TOPS vs CGTX Comparison
Compare TOPS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- CGTX
- Stock Information
- Founded
- TOPS 2000
- CGTX 2007
- Country
- TOPS Greece
- CGTX United States
- Employees
- TOPS N/A
- CGTX N/A
- Industry
- TOPS Marine Transportation
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- CGTX Health Care
- Exchange
- TOPS Nasdaq
- CGTX Nasdaq
- Market Cap
- TOPS 28.3M
- CGTX 30.0M
- IPO Year
- TOPS 2004
- CGTX 2021
- Fundamental
- Price
- TOPS $5.83
- CGTX $0.58
- Analyst Decision
- TOPS
- CGTX Strong Buy
- Analyst Count
- TOPS 0
- CGTX 6
- Target Price
- TOPS N/A
- CGTX $8.30
- AVG Volume (30 Days)
- TOPS 6.2K
- CGTX 809.4K
- Earning Date
- TOPS 03-28-2025
- CGTX 03-25-2025
- Dividend Yield
- TOPS N/A
- CGTX N/A
- EPS Growth
- TOPS N/A
- CGTX N/A
- EPS
- TOPS N/A
- CGTX N/A
- Revenue
- TOPS $83,870,000.00
- CGTX N/A
- Revenue This Year
- TOPS $7.10
- CGTX N/A
- Revenue Next Year
- TOPS $6.54
- CGTX N/A
- P/E Ratio
- TOPS N/A
- CGTX N/A
- Revenue Growth
- TOPS 1.10
- CGTX N/A
- 52 Week Low
- TOPS $5.30
- CGTX $0.34
- 52 Week High
- TOPS $14.70
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- TOPS 36.66
- CGTX 40.43
- Support Level
- TOPS $5.78
- CGTX $0.57
- Resistance Level
- TOPS $6.11
- CGTX $0.65
- Average True Range (ATR)
- TOPS 0.27
- CGTX 0.05
- MACD
- TOPS -0.01
- CGTX -0.01
- Stochastic Oscillator
- TOPS 9.99
- CGTX 9.46
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The company focuses on the transportation of petroleum products (clean and dirty) and bulk liquid chemicals. The Company is an international provider of worldwide oil, petroleum products and chemical transportation services. It generates revenue from the Time Charter agreements.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.